acetylcysteine and Epithelial Ovarian Cancer

acetylcysteine has been researched along with Epithelial Ovarian Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Bartos, P; Bartunkova, J; Chovanec, J; Cibula, D; Fucikova, J; Hraska, M; Hrnciarova, T; Kieszko, D; Klat, J; Knapp, P; Korolkiewicz, RP; Mallmann, P; Melichar, B; Minar, L; Novotny, Z; Pluta, M; Rob, L; Spacek, J; Spisek, R; Valha, P	1

Trials

1 trial(s) available for acetylcysteine and Epithelial Ovarian Cancer

Article	Year
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:1 Topics: Acetylcysteine; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Dendritic Cells; Female; Humans; Immunotherapy; Mice; Middle Aged; Paclitaxel; Young Adult	2022

Article

Year

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.

Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:1

Topics: Acetylcysteine; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Dendritic Cells; Female; Humans; Immunotherapy; Mice; Middle Aged; Paclitaxel; Young Adult

2022